Paul Davie learned the commercial life of chemistry when molecular modeling still felt like a specialist dialect. The machines were expensive, the interfaces unfamiliar, and the audience made up of scientists who could detect a woolly explanation at twenty paces. A chemistry education helped. So did beginning in user support, where every confused user delivers a small seminar on the difference between what software promises and what it actually permits.
That combination became his trade: enough technical fluency to respect the science, enough commercial discipline to build an operation around it. Across more than forty years, Davie moved through nearly every institutional form scientific software can take - university spinout, public company, consolidated platform, venture-backed startup, nonprofit data center, global software business and drug-discovery partner. His CV looks less like a sequence of jobs than a compressed industrial history.
It also contains one conspicuous excursion. After years selling tools that helped scientists understand molecules, he co-founded a company that helped organizations understand the behavior inside their databases. Oracle eventually acquired it. Davie then returned to chemistry, bringing the detour's lessons about data, trust and adoption back with him.
The question by the Silicon Graphics machine
The origin story is pleasingly unstrategic. As an Oxford undergraduate, Davie once went to ask Graham Richards, the computational chemist and entrepreneur, about a practical experiment on a then-new Silicon Graphics machine. A few weeks later, Davie found himself packing boxes at Oxford Molecular for a summer job. One technical question had opened a commercial door.
After Oxford and postgraduate work in the Surface Physics Department at the Fritz Haber Institute in West Berlin, Davie joined Chemical Design. He worked in support and then sales. The sequence mattered. Scientific customers did not need a generic pitch applied to an exotic product. They needed someone who understood the work well enough to know where the product belonged, and honest enough to know where it did not.
At Oxford Molecular, he was hired to build the European business. The company had grown out of university research and possessed the familiar spinout imbalance: abundant intellectual horsepower, less certainty about repeatable revenue. Davie's European sales arrived on forecast. In the first quarter of 1993, the company reached profit for the first time. He later led the European operation through Oxford Molecular's public listing and subsequent growth.
A fine scientific product still needs a route into daily practice.The thread running through Davie's career
This was not sales as decorative enthusiasm. It was infrastructure. Forecasts, support, local teams, customer conversations and the slow accumulation of trust turned clever software into a business. When Oxford Molecular was acquired and folded into what became Accelrys, Davie served as European general manager. Industry names changed as companies merged. The recurring problem remained: how to keep difficult tools useful while the organization around them grew.
A career through changing machines
Chemical Design: user support becomes a route into scientific sales.
Oxford Molecular records its first profitable quarter.
Secerno turns machine-learning research into database defense.
CCDC opens its North American operation at Rutgers.
Davie joins Schrödinger and helps build global software operations.
X-Chem, an announced step back, then a return to Schrödinger.
The useful detour
Secerno appears, at first, to be the odd company out. Founded in Oxford in the mid-2000s, it addressed database security rather than molecular behavior. Its technology learned the normal grammar of database activity so it could identify and block suspicious actions. Davie co-founded the company, served initially as chief executive, and later moved to chief operating officer when an experienced software executive was recruited to lead the next phase.
The move reveals something consistent in his work. Whether the object is a molecular model or a stream of database queries, the product asks customers to trust a complex system with consequential decisions. The technical merit matters; so do deployment, risk, cost and a clear account of value. Davie argued that security vendors had to offer more than the abstract virtue of being secure. Customers wanted return on investment and technology fitted to a changing infrastructure.
He also predicted that larger security companies would buy innovation rather than invent all of it internally. In 2010, Oracle acquired Secerno and incorporated its technology into Oracle Database Firewall. The price was not disclosed. The outcome was concrete: university research became a product, the product became a company, and the company became part of a global platform.
The Davie bridge
Back to molecules, now in the cloud
Davie returned to computational drug discovery as chief executive of InhibOx. The Oxford company offered virtual screening and design tools, including a large curated collection of three-dimensional molecular structures. Its work joined two strands that would soon become common: serious computation delivered as a service, and drug discovery widened by access to enormous chemical spaces.
His gift for plain comparison surfaced when discussing cloud computing for smaller biotechnology companies. Renting computing power on demand, he said, was like renting a good hotel room instead of buying a house. The metaphor survives because it preserves the business point. A small research team could reach substantial computing resources without buying and maintaining the entire estate.
“It's like renting a good hotel room instead of buying a house.”Paul Davie on cloud computing for smaller biotech companies
By 2013, he was building another kind of access. The Cambridge Crystallographic Data Centre created its North American operation inside Rutgers University's Center for Integrative Proteomics Research, near the RCSB Protein Data Bank. Davie became its general manager. The location put small-molecule structural data beside expertise in biological macromolecules, a practical neighborhood for scientists who rarely solve discovery problems with only one kind of information.
The role mixed service, science and institution-building. Roughly half of CCDC's users were in North America, and the new operation gave them closer application support across crystallography, drug discovery and materials research. Davie also served on the American Crystallographic Association's Data, Standards and Computing Committee. It was a natural assignment for a commercial operator whose work had always depended on useful scientific data moving between people and systems.
A global business, then an encore
Davie joined Schrödinger in 2017, initially leading North American software sales. He rose to executive vice president of sales and built sales, marketing and service operations around the world. Schrödinger sat at an instructive junction: its physics-based computational platform served pharmaceutical, biotechnology, materials, academic and government users, while the company also applied that platform to its own drug programs.
The commercial challenge was broader than moving licenses. A platform used by computational chemists, medicinal chemists, structural biologists and materials researchers has several vocabularies, buying processes and definitions of success. Growth depends on account management and customer support, but also on keeping the scientific reason for the product visible. Davie's early years in user support had become relevant at a much larger scale.
In June 2024, he joined X-Chem as chief business officer. The move placed him beside DNA-encoded library screening, medicinal chemistry and AI-supported informatics. He was charged with global business development, strategic partnerships and new market opportunities. The technology stack had changed beyond recognition since the Chemical Design years, but the job still joined scientific capability with an organization willing to use it.
Then, in 2025, Davie announced that he would step back from full-time executive roles. He wanted to remain connected as a board director and consultant to companies working where software meets life sciences. The responses from former colleagues supplied a warmer résumé than any corporate biography could: memories of mentorship, generosity, shared travel and a boss who took other people's development seriously.
Retirement proved negotiable. On May 18, 2026, Schrödinger's commercial chief left the company. Davie returned as interim chief commercial officer and global head of software sales and marketing while a permanent successor was sought. An interim appointment is sometimes treated as administrative punctuation. This one read more like institutional memory being called back into the room.
The unglamorous art of making science travel
Scientific businesses enjoy talking about breakthrough algorithms. They speak less often about the patient systems that allow those algorithms to travel: documentation, training, account teams, partnerships, local knowledge, reliable forecasts and support after the contract is signed. None produces a cinematic laboratory scene. All determine whether a sophisticated tool becomes part of ordinary scientific work.
Davie's career gives that hidden machinery a face. Chemistry gave him a language for the customer. Support work showed him the friction. Sales taught him to measure whether an explanation had landed. Company-building added hiring, capital, partnerships and the sobering knowledge that good technology can remain commercially stranded.
The route from Chem-X, one of Oxford Molecular's early products, to X-Chem became a private joke among former colleagues. It is also a neat description of the arc. In between sit an IPO, an acquisition by Oracle, a transatlantic data center, global software operations and the growing convergence of physics, data and machine learning in drug discovery.
Davie has said he hopes to lend his experience to younger companies and stay close to the community that shaped his life. The phrasing is modest, but the experience is unusually longitudinal. He remembers when computational chemistry was a cottage industry and has helped sell its descendants as global platforms. He has seen fashionable terms arrive after the underlying work was already underway.
Four decades can make a person nostalgic. Davie's public reflections sound more curious than wistful. He wants to see where the next generation takes the field. That may be the most durable trait in his story: after all the names, machines and markets have changed, he is still interested in what the technology can become - and in helping someone explain why it belongs in the room.